UBS Initiates Coverage On Amneal Pharmaceuticals with Buy Rating, Announces Price Target of $19

Benzinga Newsdesk www.benzinga.com Positive 53.8%

Neg 0% Neu 0% Pos 53.8%

UBS analyst Ashwani Verma initiates coverage on Amneal Pharmaceuticals (NASDAQ:AMRX) with a Buy rating and announces Price Target of $19.